The association of mediastinal mass in the formation of thrombi in pediatric patients with non-lymphoblastic lymphomas.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
02 2020
Historique:
received: 13 06 2019
revised: 07 10 2019
accepted: 10 10 2019
pubmed: 19 11 2019
medline: 23 4 2020
entrez: 19 11 2019
Statut: ppublish

Résumé

Children diagnosed with cancer are at a significantly higher risk of developing a thrombotic event (TE) compared with the general population. The rarity of these events makes it difficult to discern the specific risk factors; however, age, sex, presence of central venous lines, inherited thrombophilia, and mediastinal mass may play a role. The primary aim of this study is to identify prognostic characteristics of children diagnosed with non-lymphoblastic lymphomas associated with a greater risk of developing a TE early on in their disease, with an increased focus on mediastinal mass characteristics. Retrospective chart review of pediatric patients diagnosed with non-lymphoblastic lymphoma between 2004 and 2014 at St. Jude Children's Research Hospital. TE occurred in 8.5% (n = 28/330) of individuals at a median of 21 days from the diagnosis of a non-lymphoblastic lymphoma, with 60% of TEs occurring within 30 days of diagnosis. Of the variables evaluated, only presence of a peripherally inserted central catheter (odds ratio [OR]: 3.14 [95% CI: 1.24-7.98; P = 0.02]) and degree of superior vena cava (SVC) compression of > 25% increased the odds of developing a TE (OR: 2.2 [95% CI: 1.01-4.93; P = 0.048]). Pediatric patients with non-lymphoblastic lymphoma are at increased risk of developing TEs. In contrast to previous studies, the presence of a mediastinal mass alone was not associated with a higher risk of TE, but individuals with a mediastinal mass with 25% or greater degree of SVC compression were more likely to develop a TE. This finding highlights a high-risk group of children who may benefit from prophylactic anticoagulation.

Sections du résumé

BACKGROUND
Children diagnosed with cancer are at a significantly higher risk of developing a thrombotic event (TE) compared with the general population. The rarity of these events makes it difficult to discern the specific risk factors; however, age, sex, presence of central venous lines, inherited thrombophilia, and mediastinal mass may play a role. The primary aim of this study is to identify prognostic characteristics of children diagnosed with non-lymphoblastic lymphomas associated with a greater risk of developing a TE early on in their disease, with an increased focus on mediastinal mass characteristics.
METHODS
Retrospective chart review of pediatric patients diagnosed with non-lymphoblastic lymphoma between 2004 and 2014 at St. Jude Children's Research Hospital.
RESULTS
TE occurred in 8.5% (n = 28/330) of individuals at a median of 21 days from the diagnosis of a non-lymphoblastic lymphoma, with 60% of TEs occurring within 30 days of diagnosis. Of the variables evaluated, only presence of a peripherally inserted central catheter (odds ratio [OR]: 3.14 [95% CI: 1.24-7.98; P = 0.02]) and degree of superior vena cava (SVC) compression of > 25% increased the odds of developing a TE (OR: 2.2 [95% CI: 1.01-4.93; P = 0.048]).
CONCLUSION
Pediatric patients with non-lymphoblastic lymphoma are at increased risk of developing TEs. In contrast to previous studies, the presence of a mediastinal mass alone was not associated with a higher risk of TE, but individuals with a mediastinal mass with 25% or greater degree of SVC compression were more likely to develop a TE. This finding highlights a high-risk group of children who may benefit from prophylactic anticoagulation.

Identifiants

pubmed: 31736198
doi: 10.1002/pbc.28057
pmc: PMC7233458
mid: NIHMS1576095
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28057

Subventions

Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : CA-21765
Pays : United States

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Front Pediatr. 2017 Feb 06;5:12
pubmed: 28220143
Thromb Res. 2017 Apr;152:64-68
pubmed: 28249199
Thromb Res. 2008;122(4):459-65
pubmed: 18237767
Int J Pediatr Obes. 2010 Dec;5(6):458-60
pubmed: 20233144
Thromb Res. 2010 Apr;125 Suppl 2:S151-4
pubmed: 20433996
Blood. 2003 Jun 1;101(11):4273-8
pubmed: 12560228
J Pediatr. 2011 Jul;159(1):133-7
pubmed: 21353248
Thromb Res. 2006;118(1):137-52
pubmed: 16039698
Pediatr Blood Cancer. 2008 Dec;51(6):792-7
pubmed: 18798556
Thromb Res. 2011 Aug;128(2):130-4
pubmed: 21492908

Auteurs

Jessica Gartrell (J)

Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
University of Tennessee Health Science Center, Memphis, Tennessee.

Sue C Kaste (SC)

University of Tennessee Health Science Center, Memphis, Tennessee.
Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, Tennessee.

John T Sandlund (JT)

Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
University of Tennessee Health Science Center, Memphis, Tennessee.

Jamie Flerlage (J)

Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
University of Tennessee Health Science Center, Memphis, Tennessee.

Yinmei Zhou (Y)

Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.

Cheng Cheng (C)

Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.

Jeremie Estepp (J)

University of Tennessee Health Science Center, Memphis, Tennessee.
Department of Hematology, St Jude Children's Research Hospital, Memphis, Tennessee.

Monika L Metzger (ML)

Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
University of Tennessee Health Science Center, Memphis, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH